Evista gets FDA approval for new use to reduce breast cancer risk
INDIANAPOLIS The Food and Drug Administration has approved a new application for Eli Lilly’s osteoporosis drug Evista. The drug is now indicated as a way to reduce the risk of invasive breast cancer.
The drug’s new use is designed for postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer. “The FDA’s decision marks a major milestone. For the first time, postmenopausal women with osteoporosis will have one treatment option that can help address two leading health concerns—osteoporosis and invasive breast cancer,” said Gwen Krivi, vice president of Lilly Research Laboratories.
The approval comes less than a year after the application was submitted to the FDA and also carries a recommendation of the Oncologics Drug Advisory Committee.
GSK will supply over 30 million doses of flu vaccines to U.S. this season
PHILADELPHIA The influenza virus vaccines Fluarix and FluLaval from GlaxoSmithKline will have a combined total of 30 million to 35 million doses supplied to the U.S. markets for the 2007-08 influenza season.
The vaccines will be delivered in phased approach for the rest of September and all of October with completion occurring at the end of October. “Providing an ample and steadily growing supply of flu vaccine has been a priority for GlaxoSmithKline since entering the U.S. market in 2004,” said David Pernock, senior vice president of GSK. “Over the years, GSK has significantly increased its influenza vaccine manufacturing capacity, and we have taken steps to improve the way this product is distributed to those who need it.”
Last year, the company sent about 25 million doses of the drugs for flu season.
NACDS pledges to award at least $100,000 in scholarships
ALEXANDRIA, Va. The National Association of Chain Drug Stores Foundation is pledging to award at least $100,000 this year in scholarships, and has begun accepting applications.
Last year, 40 students were awarded a scholarship, an increase of three from 2005, and this year it looks like the foundation wants to add award the scholarship of $2,000 to at least 50 students. Also, some select recipients will receive named scholarships in the amount of $2,500, in addition to the $2,000 scholarship.
Applicants must be at least in their second year of pharmacy school, as well as have experience and the desire to work in a chain community pharmacy.
“The NACDS Foundation is continuously committed to advancing the pharmacy industry for the good of the public. An important part of our industry is its future, and that is what these students represent,” said Phil Schneider, NACDS Foundation president. The deadline for all applications is Oct. 19.